Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

2-Methyltryptamine

Add links
From Wikipedia, the free encyclopedia
(Redirected from 2-methyltryptamine)

2-Methyltryptamine
Clinical data
Other names2-MT; 2-Me-T; 2-Methyl-T
Drug classSerotonin receptor agonist
ATC code
  • None
Identifiers
  • 2-(2-methyl-1H-indol-3-yl)ethanamine
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.018.498 Edit this at Wikidata
Chemical and physical data
FormulaC11H14N2
Molar mass174.247 g·mol−1
3D model (JSmol)
  • CC1=C(C2=CC=CC=C2N1)CCN
  • InChI=1S/C11H14N2/c1-8-9(6-7-12)10-4-2-3-5-11(10)13-8/h2-5,13H,6-7,12H2,1H3
  • Key:CPVSLHQIPGTMLH-UHFFFAOYSA-N

2-Methyltryptamine (2-MT, 2-Me-T, or 2-methyl-T) is a serotonin receptor agonist of the tryptamine family.[1][2][3] It shows dramatically reduced activity at serotonin receptors compared to tryptamine[2][3] and mixed effects in terms of psychedelic-like effects in animals.[1][3]

Pharmacology

[edit]

Pharmacodynamics

[edit]

2-MT shows affinity (Ki) for the serotonin 5-HT1A and 5-HT2A receptors, with Ki values of 1,095 nM and 7,774 nM, respectively.[2][3] These affinities were respectively 34-fold and 3.2-fold lower than those of tryptamine in the same study.[2][3] It also acts as an agonist of the serotonin 5-HT1A and 5-HT2A receptors, with EC50Tooltip half-maximal effective concentration values of 12,534 nM and 4,598 nM, respectively.[3] These activational potencies were respectively 14-fold and 19-fold lower than those of tryptamine in the same study.[3]

It does not produce conditioned place preference (CPP), self-administration, or changes in locomotor activity in rodents.[1] Findings on whether 2-MT produces the head-twitch response (HTR), a behavioral proxy of psychedelic effects, are mixed.[1][3][2] In one study, it produced the HTR at a dose of 3 mg/kg intraperitoneally, and this was completely blocked by the serotonin 5-HT2A receptor antagonist ketanserin.[1] In another study, both tryptamine and 2-MT did not produce the HTR at a dose of 3 mg/kg intraperitoneally.[3][2]

Chemistry

[edit]

Derivatives

[edit]

A number of derivatives of 2-MT are known, including:[4]

These drugs were synthesized and tested by Alexander Shulgin.[4] He found that the drugs in this group became orally active but generally produced no or only mild psychedelic effects (with the exception of 2-Me-5-MeO-DMT).[4] Instead, they caused effects like tactile enhancement and auditory distortion, among others.[4]

A few other derivatives, including 2-methyl-DiPT, 2-methyl-iPALT, 2-methyl-5-MeO-DALT, and 2-methyl-5-F-DALT, are also known.[4][5][6]

Further derivatives of 2-MT include the following:

EMD-386088 (2-methyl-5-chloro-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole) isn't technically a tryptamine but is very similar and is a serotonin 5-HT6 receptor partial agonist as well as having moderate affinity for the serotonin 5-HT3 receptor and acting as a dopamine reuptake inhibitor.

Yet another related compound is 2-HO-NMT, a tryptamine alkaloid.

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 Abiero A, Ryu IS, Botanas CJ, Custodio RJ, Sayson LV, Kim M, et al. (January 2020). "Four Novel Synthetic Tryptamine Analogs Induce Head-Twitch Responses and Increase 5-HTR2a in the Prefrontal Cortex in Mice". Biomolecules & Therapeutics. 28 (1): 83–91. doi:10.4062/biomolther.2019.049. PMC 6939696. PMID 31230432.
  2. 1 2 3 4 5 6 Chen X, Li J, Yu L, Maule F, Chang L, Gallant JA, et al. (October 2023). "A cane toad (Rhinella marina) N-methyltransferase converts primary indolethylamines to tertiary psychedelic amines". The Journal of Biological Chemistry. 299 (10) 105231. doi:10.1016/j.jbc.2023.105231. PMC 10570959. PMID 37690691.
  3. 1 2 3 4 5 6 7 8 9 Chen X, Li J, Yu L, Dhananjaya D, Maule F, Cook S, et al. (10 March 2023), Bioproduction platform using a novel cane toad (Rhinella marina) N-methyltransferase for psychedelic-inspired drug discovery (PDF), doi:10.21203/rs.3.rs-2667175/v1, retrieved 17 March 2025
  4. 1 2 3 4 5 Shulgin A, Shulgin A (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.
  5. ↑ Klein LM, Cozzi NV, Daley PF, Brandt SD, Halberstadt AL (November 2018). "Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs". Neuropharmacology. 142: 231–239. doi:10.1016/j.neuropharm.2018.02.028. PMC 6230509. PMID 29499272.
  6. ↑ US 20240277665A1, Daley PF, Cozzi NV, Callaway WB, "Asymmetric allyl tryptamines", issued 4 March 2024, assigned to Alexander Shulgin Research Institute Inc.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=2-Methyltryptamine&oldid=1353911925"